138 lines
5.3 KiB
Plaintext
138 lines
5.3 KiB
Plaintext
Newsgroups: alt.drugs
|
|
From: andersom@spot.Colorado.EDU (Marc Anderson)
|
|
Subject: Lester Grinspoon at Colo
|
|
Message-ID: <1993Jul28.004812.4401@ucsu.Colorado.EDU>
|
|
Date: Wed, 28 Jul 1993 00:48:12 GMT
|
|
|
|
-----BEGIN PGP SIGNED MESSAGE-----
|
|
|
|
Dr. Grinspoon gave a speech last Friday in Denver about his new book
|
|
_Forbidden Medicine_ and medical marijuana in general. I got there
|
|
late but enjoyed a good deal of his talk, including a panel discussion
|
|
with a doctor from the Colorado Health Sciences Center (Colorado's Med
|
|
School) -- uhm, Dr. Robinson(?), I think it was... The talk was very
|
|
un-technical, and a lot of the data was anecdotal (Grinspoon acknowledged
|
|
this, and it's understandable due to the target audience). He really
|
|
did impress me as being someone who knew what he was talking about, though.
|
|
I hooked up with him after and asked him a few questions on his opinions
|
|
about the ultimate dangers of cannabis (respiratory system, and its
|
|
carcinogenicity), and his basic response was that, once we can get it
|
|
legalized, this problem would be solved very quickly. (i.e., with vaporizers,
|
|
etc.)
|
|
|
|
The doctor from CHSC was an oncologist, and he was fairly critical of
|
|
Grinspoon, although, Grinspoon held his ground well. However, Dr. Robinson
|
|
did seem in favor of making cannabis available for medical purposes. I
|
|
asked Dr. Robinson what his opinion is on the possible significance of
|
|
Po 210 in tobacco carcinogenicity, and he said that the other agents in
|
|
tobacco probably override this danger...
|
|
|
|
Dr. Grinspoon's book seems cool, although, again, much of it is based
|
|
on anecdotal evidence he has received from personal connections. It still
|
|
appeared to have a good number of references. I'm probably gonna pick
|
|
it up in a few weeks when I get some money.
|
|
|
|
One of the interesting things Grinspoon talked about is cannabis' use in
|
|
treating multiple sclerosis, of which, he mostly talked about anecdotal
|
|
results reported in his book. I cross-ref'd cannabis and multiple
|
|
sclerosis through paperchase and came up with a few refs which I'll attach
|
|
to this post.
|
|
|
|
oh, and btw: Dr. Grinspoon's fax # is 617-277-8423, for anyone interested
|
|
in getting in touch with him.
|
|
|
|
- -marc
|
|
andersom@spot.colorado.edu
|
|
|
|
|
|
1
|
|
AU - Petro DJ
|
|
AU - Ellenberger C Jr
|
|
TI - Treatment of human spasticity with delta 9-tetrahydrocannabinol.
|
|
AB - Spasticity is a common neurologic condition in patients with multiple
|
|
sclerosis, stroke, cerebral palsy or an injured spinal cord. Animal
|
|
studies suggest that THC has an inhibitory effect on polysynaptic
|
|
reflexes. Some spastic patients claim improvement after inhaling
|
|
cannabis. We tested muscle tone, reflexes, strength and performed
|
|
EMGs before and after double-blinded oral administration of either 10
|
|
or 5 mg THC or placebo. The blinded examiner correctly identified the
|
|
trials in which the patients received THC in seven of nine cases. For
|
|
the group, 10 mg THC significantly reduced spasticity by clinical
|
|
measurement (P less than 0.01). Quadriceps EMG interference pattern
|
|
was reduced in those four patients with primarily extensor
|
|
spasticity. THC was administered to eight other patients with
|
|
spasticity and other CNS lesions. Responses varied, but benefit was
|
|
seen in three of three patients with "tonic spasms." No benefit was
|
|
noted in patients with cerebellar disease.
|
|
SO - J Clin Pharmacol 1981 Aug-Sep;21(8-9 Suppl):413S-416S
|
|
DP - 1981 Aug-Sep
|
|
TA - J Clin Pharmacol
|
|
PG - 413S-416S
|
|
IP - 8-9 Suppl
|
|
VI - 21
|
|
IS - 0091-2700
|
|
UI - 82053565
|
|
|
|
2
|
|
AU - Ungerleider JT
|
|
AU - Andyrsiak T
|
|
AU - Fairbanks L
|
|
AU - Ellison GW
|
|
AU - Myers LW
|
|
TI - Delta-9-THC in the treatment of spasticity associated with multiple
|
|
sclerosis.
|
|
AB - Marijuana is reported to decrease spasticity in patients with
|
|
multiple sclerosis. This is a double blind, placebo controlled,
|
|
crossover clinical trial of delta-9-THC in 13 subjects with clinical
|
|
multiple sclerosis and spasticity. Subjects received escalating doses
|
|
of THC in the range of 2.5-15 mg., five days of THC and five days of
|
|
placebo in randomized order, divided by a two-day washout period.
|
|
Subjective ratings of spasticity and side effects were completed and
|
|
semiquantitative neurological examinations were performed. At doses
|
|
greater than 7.5 mg there was significant improvement in patient
|
|
ratings of spasticity compared to placebo. These positive findings in
|
|
a treatment failure population suggest a role for THC in the
|
|
treatment of spasticity in multiple sclerosis.
|
|
AD - Department of Psychiatry
|
|
AD - U.C.L.A. School of Medicine 90024.
|
|
SO - Adv Alcohol Subst Abuse 1987;7(1):39-50
|
|
DP - 1987
|
|
TA - Adv Alcohol Subst Abuse
|
|
PG - 39-50
|
|
IP - 1
|
|
VI - 7
|
|
IS - 0270-3106
|
|
UI - 88160795
|
|
|
|
3
|
|
AU - Clifford DB
|
|
TI - Tetrahydrocannabinol for tremor in multiple sclerosis.
|
|
AB - Based on one patient's enthusiastic report, eight patients with
|
|
multiple sclerosis, seriously disabled with tremor and ataxia, were
|
|
given oral tetrahydrocannabinol. Two demonstrated improved motor
|
|
coordination.
|
|
SO - Ann Neurol 1983 Jun;13(6):669-71
|
|
DP - 1983 Jun
|
|
TA - Ann Neurol
|
|
PG - 669-71
|
|
IP - 6
|
|
VI - 13
|
|
UI - 83281524
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-----BEGIN PGP SIGNATURE-----
|
|
Version: 2.3a
|
|
|
|
iQBVAgUBLFXMu8UtKvnPICaNAQGDrwIAs4u4WBdP8s1rfYnaKCmRCXiGFkOZKEli
|
|
ek4HQlobS9dhJ43KhYFyxMxBRa8GMaLFMKHAieAriJ+SFxy/Svzfkw==
|
|
=5atI
|
|
-----END PGP SIGNATURE-----
|
|
|
|
|